Background
Phase III, double-blind, placebo-controlled RCT (AETHERA). 329 patients with classical Hodgkin lymphoma at high risk of relapse after autologous stem cell transplantation (ASCT). High-risk defined as: primary refractory disease, relapse within 12 months of frontline therapy, or relapse with extranodal disease. Patients started treatment within 30–45 days after ASCT.
Interventions and follow up
Arm A: Brentuximab vedotin (BV) 1.8 mg/kg IV q3w × 16 cycles post-ASCT (n=165)
Arm B: Placebo q3w × 16 cycles post-ASCT (n=164)
Primary endpoint: PFS (investigator-assessed, ITT)
Median follow up: 5 years (Moskowitz, Blood 2018)
Arm B: Placebo q3w × 16 cycles post-ASCT (n=164)
Primary endpoint: PFS (investigator-assessed, ITT)
Median follow up: 5 years (Moskowitz, Blood 2018)
Results
5-yr PFS (BV vs. placebo): 59% vs. 41%, HR 0.52 (95% CI 0.38–0.72)
5-yr OS: not significantly different — HR 0.72 (95% CI 0.44–1.17); salvage effective at relapse in placebo arm
Median PFS (BV vs. placebo): 42.9 months vs. 24.1 months
5-yr OS: not significantly different — HR 0.72 (95% CI 0.44–1.17); salvage effective at relapse in placebo arm
Median PFS (BV vs. placebo): 42.9 months vs. 24.1 months
Adverse events
Neurologic (BV vs. placebo): peripheral neuropathy 67% vs. 32%; grade ≥3 13% vs. 1%
Hematologic: neutropenia grade ≥3 35% vs. 12%
Tolerability: dose reductions required in 32%; discontinuations due to AE 33%; most peripheral neuropathy resolved or improved with dose reduction/discontinuation
Hematologic: neutropenia grade ≥3 35% vs. 12%
Tolerability: dose reductions required in 32%; discontinuations due to AE 33%; most peripheral neuropathy resolved or improved with dose reduction/discontinuation
Conclusions
Post-ASCT consolidation with BV significantly reduced the risk of progression (HR 0.52, 5-yr PFS 59% vs. 41%) in high-risk cHL, without a significant OS benefit, establishing BV as the standard consolidation for high-risk patients after ASCT. FDA approved August 2015 for post-ASCT consolidation.
Key Limitations
No OS benefit despite PFS improvement — likely due to effective salvage (PD-1 inhibitors) for patients who relapse post-ASCT, blunting the survival advantage of consolidation. The high peripheral neuropathy rate (67%) with a 33% discontinuation rate raises questions about the benefit-risk balance, particularly given that PD-1 inhibitors (pembrolizumab, nivolumab) are effective in the same relapse setting. Patient selection for high-risk was not precisely defined, and practice has evolved since enrollment (pembrolizumab now often used before ASCT). In the current era where PD-1 inhibitors are used pre-ASCT as salvage, the post-ASCT risk profile may differ.
Clinical Context
AETHERA established BV post-ASCT consolidation as FDA-approved standard for high-risk cHL (August 2015). However, its clinical utility is debated in the era of effective PD-1 inhibitor-based salvage (pembrolizumab pre-ASCT with high CR rates in pembro-GVD), where patients bridged to ASCT in deep remission may have lower relapse risk. BV post-ASCT remains an option for high-risk patients while practice continues to evolve.